Cytotoxicity of Cannabinoids in Combination with Traditional Lymphoma Chemotherapeutic Drugs Against Non-Hodgkin’s Lymphoma

<b>Background</b>: Cannabinoids (CBs) are FDA-approved for mitigating chemotherapy-induced side effects such as pain, nausea, and loss of appetite. Beyond palliative care, CBs exhibit anti-tumor properties in various cancers, including non-Hodgkin’s lymphoma (NHL). Previously, we demonstrated the cy...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Saba Omer, Mahmoud Mansour, Satyanarayana R Pondugula, Muralikrishnan Dhanasekaran, Brad Matz, Omer Khan, Dawn Boothe
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2025-12-01
Serie:	Biomedicines
Soggetti:	lymphoma cannabinoids CHOP combination therapy cancer
Accesso online:	https://www.mdpi.com/2227-9059/14/1/3
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!